Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Alexandria Hammond Wolfe Research, LLC Good morning, everybody. My name is Alex Hammond, and I’m the biopharma analyst here at Wolfe. So it’s my pleasure today to have J&J. So we have Candice Long, Worldwide VP, Immunology, Global Commercial Strategy; and we have David Lee, Global Immunology Therapeutic Area Head. Thank you guys so much for joining us. Alexandria Hammond Wolfe Research, LLC So obviously, a lot going on at J&J. Maybe starting off with icotrokinra. So obviously, we know that there is a submission to regulators. How should we kind of think about next steps? When could we see approval? And have you guys started preparing for launch as of today? David Lee Global Therapeutic Area Head, Immunology for Janssen Pharmaceutical Sure. Well, I maybe will start. Let’s start with icotrokinra. It’s the first targeted oral peptide to the — highly selective to the IL-23 receptor. We see this as a transformative next-generation therapy for the field. And we see that because it is the only asset that provides the unprecedented combination of complete skin clearance, favorable safety, of course, with the simplicity of a single pill once a day. Now our development program has been robust to inform questions, and we see this profile as now becoming first-line systemic therapy for psoriasis. We say that because of the data that we have provided in our large Phase III studies with adults with moderate-to-severe psoriasis, with adolescents with moderate-to-severe psoriasis, as well as in.
https://seekingalpha.com/article/4844700-johnson-and-johnson-jnj-presents-at-7th-annual-wolfe-research-healthcare-conference?source=feed_all_articles